Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: Can acetylcholine levels in the brain be improved in alzheimer's disease?
- 1 January 1988
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 14 (3-4) , 235-246
- https://doi.org/10.1002/ddr.430140315
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The effects of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intra ventricular administration in beagle dogsNeuropharmacology, 1986
- Distribution of the molecular forms of acetylcholinesterase in human brain: Alterations in dementia of the Alzheimer typeAnnals of Neurology, 1986
- Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patientsActa Anaesthesiologica Scandinavica, 1986
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983
- Reduced lumbar CSF somatostatin in levels in Alzheimer's diseaseLife Sciences, 1982
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982
- Coenzyme a-acetylating enzymes in Alzheimer's disease: Possible cholinergic ‘compartment’ of pyruvate dehydrogenaseNeuroscience Letters, 1980
- Acetylcholinesterase activity in ventricular and cisternal csf of dogs: Effect of chlorpromazineJournal of Neuroscience Research, 1978